Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VTYX |
---|---|---|
09:32 ET | 2532 | 2.11 |
09:34 ET | 200 | 2.1001 |
09:36 ET | 3227 | 2.11 |
09:38 ET | 100 | 2.11 |
09:41 ET | 200 | 2.1197 |
09:43 ET | 7390 | 2.1333 |
09:45 ET | 824 | 2.13 |
09:48 ET | 2100 | 2.13 |
09:50 ET | 1000 | 2.125 |
09:52 ET | 100 | 2.125 |
09:54 ET | 1425 | 2.1105 |
09:56 ET | 3700 | 2.11 |
09:57 ET | 100 | 2.105 |
09:59 ET | 7490 | 2.105 |
10:03 ET | 1750 | 2.095 |
10:06 ET | 500 | 2.095 |
10:08 ET | 500 | 2.0992 |
10:10 ET | 3990 | 2.09 |
10:12 ET | 2900 | 2.075 |
10:14 ET | 1941 | 2.07 |
10:15 ET | 896 | 2.07 |
10:17 ET | 1800 | 2.0789 |
10:19 ET | 2460 | 2.085 |
10:21 ET | 398 | 2.08 |
10:24 ET | 225 | 2.07 |
10:26 ET | 10188 | 2.065 |
10:28 ET | 2086 | 2.065 |
10:30 ET | 9587 | 2.075 |
10:32 ET | 300 | 2.075 |
10:33 ET | 3869 | 2.08 |
10:37 ET | 600 | 2.08 |
10:39 ET | 500 | 2.085 |
10:42 ET | 200 | 2.075 |
10:44 ET | 500 | 2.075 |
10:46 ET | 485 | 2.075 |
10:48 ET | 500 | 2.075 |
10:50 ET | 700 | 2.075 |
10:51 ET | 2479 | 2.085 |
10:53 ET | 1200 | 2.0891 |
10:55 ET | 1300 | 2.095 |
10:57 ET | 200 | 2.095 |
11:00 ET | 200 | 2.095 |
11:02 ET | 400 | 2.095 |
11:04 ET | 1124 | 2.0892 |
11:06 ET | 300 | 2.085 |
11:08 ET | 300 | 2.085 |
11:09 ET | 300 | 2.085 |
11:11 ET | 200 | 2.085 |
11:13 ET | 300 | 2.08 |
11:15 ET | 2486 | 2.08 |
11:18 ET | 200 | 2.085 |
11:20 ET | 2535 | 2.085 |
11:22 ET | 1400 | 2.085 |
11:24 ET | 1155 | 2.075 |
11:26 ET | 800 | 2.075 |
11:27 ET | 300 | 2.075 |
11:29 ET | 1757 | 2.07 |
11:31 ET | 400 | 2.07 |
11:33 ET | 400 | 2.075 |
11:36 ET | 2300 | 2.075 |
11:38 ET | 500 | 2.07 |
11:40 ET | 200 | 2.075 |
11:42 ET | 685 | 2.075 |
11:44 ET | 8743 | 2.075 |
11:45 ET | 3357 | 2.065 |
11:47 ET | 4273 | 2.06 |
11:49 ET | 400 | 2.065 |
11:51 ET | 2832 | 2.06 |
11:54 ET | 897 | 2.065 |
11:56 ET | 679 | 2.065 |
11:58 ET | 1989 | 2.065 |
12:00 ET | 800 | 2.07 |
12:02 ET | 549 | 2.06 |
12:03 ET | 100 | 2.06 |
12:05 ET | 656 | 2.06 |
12:07 ET | 200 | 2.06 |
12:09 ET | 444 | 2.065 |
12:12 ET | 1150 | 2.06 |
12:14 ET | 400 | 2.06 |
12:16 ET | 467 | 2.065 |
12:18 ET | 2845 | 2.075 |
12:20 ET | 2838 | 2.085 |
12:21 ET | 300 | 2.085 |
12:25 ET | 204 | 2.085 |
12:27 ET | 100 | 2.085 |
12:30 ET | 200 | 2.08 |
12:32 ET | 100 | 2.08 |
12:34 ET | 200 | 2.085 |
12:36 ET | 100 | 2.08 |
12:38 ET | 900 | 2.085 |
12:39 ET | 300 | 2.085 |
12:41 ET | 3247 | 2.09 |
12:43 ET | 357 | 2.0892 |
12:45 ET | 1435 | 2.085 |
12:48 ET | 1480 | 2.085 |
12:50 ET | 400 | 2.085 |
12:52 ET | 923 | 2.0892 |
12:54 ET | 1390 | 2.07 |
12:56 ET | 200 | 2.07 |
12:57 ET | 1195 | 2.0793 |
12:59 ET | 7534 | 2.07 |
01:01 ET | 100 | 2.07 |
01:03 ET | 348 | 2.07 |
01:06 ET | 765 | 2.08 |
01:08 ET | 2268 | 2.08 |
01:10 ET | 2805 | 2.0891 |
01:12 ET | 200 | 2.085 |
01:14 ET | 200 | 2.085 |
01:15 ET | 380 | 2.085 |
01:17 ET | 718 | 2.085 |
01:19 ET | 100 | 2.085 |
01:21 ET | 100 | 2.085 |
01:24 ET | 1007 | 2.0801 |
01:26 ET | 460 | 2.08 |
01:28 ET | 700 | 2.075 |
01:30 ET | 100 | 2.075 |
01:32 ET | 340 | 2.075 |
01:33 ET | 420 | 2.07 |
01:35 ET | 400 | 2.075 |
01:37 ET | 1060 | 2.075 |
01:39 ET | 802 | 2.08 |
01:42 ET | 9580 | 2.07 |
01:44 ET | 498 | 2.08 |
01:46 ET | 800 | 2.08 |
01:48 ET | 300 | 2.086 |
01:50 ET | 209 | 2.0812 |
01:51 ET | 7450 | 2.09 |
01:53 ET | 640 | 2.085 |
01:55 ET | 100 | 2.085 |
01:57 ET | 200 | 2.085 |
02:00 ET | 380 | 2.085 |
02:02 ET | 1600 | 2.085 |
02:04 ET | 724 | 2.086 |
02:06 ET | 440 | 2.085 |
02:08 ET | 480 | 2.085 |
02:09 ET | 620 | 2.085 |
02:11 ET | 520 | 2.085 |
02:13 ET | 200 | 2.085 |
02:18 ET | 300 | 2.085 |
02:20 ET | 450 | 2.085 |
02:22 ET | 400 | 2.085 |
02:24 ET | 708 | 2.086 |
02:26 ET | 240 | 2.085 |
02:27 ET | 400 | 2.085 |
02:29 ET | 870 | 2.0801 |
02:31 ET | 500 | 2.085 |
02:33 ET | 1697 | 2.085 |
02:36 ET | 440 | 2.085 |
02:38 ET | 440 | 2.085 |
02:40 ET | 100 | 2.085 |
02:42 ET | 340 | 2.09 |
02:44 ET | 980 | 2.085 |
02:45 ET | 360 | 2.085 |
02:47 ET | 440 | 2.0813 |
02:49 ET | 220 | 2.085 |
02:51 ET | 429 | 2.085 |
02:54 ET | 4039 | 2.095 |
02:56 ET | 280 | 2.095 |
02:58 ET | 1606 | 2.095 |
03:00 ET | 1420 | 2.095 |
03:02 ET | 1183 | 2.095 |
03:03 ET | 680 | 2.095 |
03:05 ET | 400 | 2.095 |
03:07 ET | 300 | 2.0901 |
03:09 ET | 719 | 2.0922 |
03:12 ET | 1820 | 2.095 |
03:14 ET | 2000 | 2.095 |
03:16 ET | 10364 | 2.1036 |
03:18 ET | 2100 | 2.105 |
03:20 ET | 2740 | 2.11 |
03:21 ET | 780 | 2.106 |
03:23 ET | 13476 | 2.115 |
03:25 ET | 766 | 2.115 |
03:27 ET | 489 | 2.12 |
03:30 ET | 1334 | 2.11 |
03:32 ET | 1404 | 2.115 |
03:34 ET | 660 | 2.115 |
03:36 ET | 700 | 2.115 |
03:38 ET | 880 | 2.11 |
03:39 ET | 700 | 2.115 |
03:41 ET | 1281 | 2.1113 |
03:43 ET | 15452 | 2.115 |
03:45 ET | 400 | 2.115 |
03:48 ET | 1334 | 2.115 |
03:50 ET | 1020 | 2.115 |
03:52 ET | 2501 | 2.115 |
03:54 ET | 400 | 2.115 |
03:56 ET | 28179 | 2.115 |
03:57 ET | 24441 | 2.105 |
03:59 ET | 152634 | 2.1 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ventyx Biosciences Inc | 148.4M | -0.8x | --- |
Actuate Therapeutics Inc | 145.7M | 0.0x | --- |
Immunic Inc | 145.0M | -1.1x | --- |
Context Therapeutics Inc | 144.0M | -1.8x | --- |
Acumen Pharmaceuticals Inc | 142.4M | -2.1x | --- |
Kodiak Sciences Inc | 140.0M | -0.7x | --- |
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $148.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.79 |
Book Value | $4.12 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.